Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data
Epilepsia2018Vol. 59(9), pp. 1727–1739
Citations Over TimeTop 10% of 2018 papers
Alexandra Rohracher, Georg Zimmermann, Vicente Villanueva, Íñigo Garamendi, Josemir W. Sander, Tim Wehner, Rohit Shankar, Elinor Ben‐Menachem, Martin J. Brodie, Max C. Pensel, Giancarlo Di Gennaro, Aude Maurousset, Adam Strzelczyk, Sylvain Rheims, Áttila Rácz, Katja Menzler, Vicente Bertol‐Alegre, Irene García‐Morales, Francisco Javier López‐González, Manuel Toledo, Katherine J. Carpenter, Eugen Trinka
Abstract
Across a large, treatment-resistant population, add-on perampanel was retained for ≥1 year by 48% of individuals, and 9% were seizure-free for ≥6 months. TEAEs were in line with previous reports in routine clinical use, and less frequent than in the clinical trial setting. No new or unexpected TEAEs were seen. Despite the limitations of observational studies, our data indicate that some individuals may derive a marked benefit from the use of perampanel.
Related Papers
- → Perampanel—new promise for refractory epilepsy?(2012)57 cited
- → Perampanel Treatment for Refractory Status Epilepticus in a Neurological Intensive Care Unit(2019)27 cited
- → Influence of stiripentol on perampanel serum levels(2020)8 cited
- → Clinical Characteristics of Excellent Responder of Perampanel in Epilepsy(2019)